Silverarc Capital Management, LLC Halozyme Therapeutics, Inc. Transaction History

Silverarc Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$31.97 - $41.06 $2.27 Million - $2.92 Million	-71,009 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$31.82 - $40.75 $344,896 - $441,689	10,839 Added 18.01%	71,009 $2.86 Million
Q3 2021 Nov 15, 2021	SELL	$38.47 - $46.42 $250,170 - $301,869	-6,503 Reduced 9.75%	60,170 $2.45 Million
Q2 2021 Aug 16, 2021	SELL	$38.84 - $51.31 $1.49 Million - $1.96 Million	-38,272 Reduced 36.47%	66,673 $3.03 Million
Q1 2021 May 18, 2021	BUY	$39.51 - $51.45 $195,376 - $254,420	4,945 Added 4.95%	104,945 $4.38 Million
Q4 2020 Feb 16, 2021	BUY	$25.81 - $43.62 $2.58 Million - $4.36 Million	100,000 New	100,000 $4.27 Million

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.